MENU

Stories

Three USC researchers win $4.3 million in awards from California’s stem cell agency

Three scientists from Keck Medicine of USC have won grants exceeding $4.3 million from the California Institute for Regenerative Medicine (CIRM) for research that includes creating a temporary liver for patients, finding novel ways to treat immune disorders and blood diseases, and developing new animal models for heart failure, diabetes and neurodegenerative diseases. The grants, …

Local high school students graduate from USC’s summer stem cell program

Enthusiastic is the word to best describe the students from this year’s USC’s Early Investigator High School (EiHS) Stem Cell Research Program. Ten students graduated from the summer laboratory immersion program at a ceremony held at noon on Friday, July 31 at the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research …

New USC course follows human development from stem cells to sternum

What don’t we know about human development, and what can go wrong? By focusing on these two big questions, a new 2-unit fall course will provide USC undergraduates with the opportunity to go beyond the standard developmental biology course work. In MEDS 335 — Human Development: From Stem to Sternum — students will learn about …

USC Stem Cell researchers poke around for blood genes

Even though the transplantation of blood stem cells, also known as bone marrow, has saved many lives over many decades, the genes that control the number or function of blood stem cells are not fully understood. In a study published in June in Stem Cell Reports, the USC Stem Cell labs of Hooman Allayee and …

USC researcher learns how to break a sweat

Without sweat, we would overheat and die. In a recent paper in the journal Public Library of Science One (PLOS ONE), USC faculty member Krzysztof Kobielak and a team of researchers explored the ultimate origin of this sticky, stinky but vital substance — sweat gland stem cells. Kobielak and his team used a system to …

Pfizer’s J. Jean Cui explains modern drug discovery

Only five percent of potential cancer drugs make it from phase I clinical trail to FDA approval, but J. Jean Cui, PhD, associate research fellow at Pfizer, beat the odds. Cui visited the Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research on Friday, September 13, to share her perspective on …

Marie Rippen

Stay connected.